CN1267152C - 聚乙二醇-干扰素α冻干制剂 - Google Patents
聚乙二醇-干扰素α冻干制剂 Download PDFInfo
- Publication number
- CN1267152C CN1267152C CNB031409555A CN03140955A CN1267152C CN 1267152 C CN1267152 C CN 1267152C CN B031409555 A CNB031409555 A CN B031409555A CN 03140955 A CN03140955 A CN 03140955A CN 1267152 C CN1267152 C CN 1267152C
- Authority
- CN
- China
- Prior art keywords
- lyophilized formulations
- interferon
- polyethylene glycol
- alpha
- interferon alpha
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940079322 interferon Drugs 0.000 title claims abstract description 71
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000003223 protective agent Substances 0.000 claims abstract description 37
- 239000004475 Arginine Substances 0.000 claims abstract description 31
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 31
- 239000004220 glutamic acid Substances 0.000 claims abstract description 27
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 27
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 26
- 229930195725 Mannitol Natural products 0.000 claims abstract description 26
- 239000000594 mannitol Substances 0.000 claims abstract description 26
- 235000010355 mannitol Nutrition 0.000 claims abstract description 26
- 150000002016 disaccharides Chemical class 0.000 claims abstract description 17
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 15
- 239000000945 filler Substances 0.000 claims abstract description 8
- 239000004698 Polyethylene Substances 0.000 claims description 64
- -1 polyethylene Polymers 0.000 claims description 64
- 229920000573 polyethylene Polymers 0.000 claims description 64
- 238000009472 formulation Methods 0.000 claims description 39
- 239000000203 mixture Substances 0.000 claims description 39
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 15
- 108010047761 Interferon-alpha Proteins 0.000 claims description 14
- 102000006992 Interferon-alpha Human genes 0.000 claims description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 13
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 239000000872 buffer Substances 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000008351 acetate buffer Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 239000005720 sucrose Substances 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 2
- 229930091371 Fructose Natural products 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 230000003385 bacteriostatic effect Effects 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 3
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 3
- 150000001483 arginine derivatives Chemical class 0.000 claims 3
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 claims 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 claims 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims 1
- 230000035699 permeability Effects 0.000 abstract description 5
- 239000003381 stabilizer Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000002307 glutamic acids Chemical class 0.000 abstract 1
- 229920000151 polyglycol Polymers 0.000 abstract 1
- 239000010695 polyglycol Substances 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000004108 freeze drying Methods 0.000 description 21
- 230000004071 biological effect Effects 0.000 description 20
- 230000008569 process Effects 0.000 description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 238000007710 freezing Methods 0.000 description 5
- 230000008014 freezing Effects 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 230000000975 bioactive effect Effects 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002528 anti-freeze Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-M lysinate Chemical compound NCCCCC(N)C([O-])=O KDXKERNSBIXSRK-UHFFFAOYSA-M 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000013923 monosodium glutamate Nutrition 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940073490 sodium glutamate Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
试样 | 0个月 | 6个月 | 12个月 | 18个月 | 24个月 | |
1 | 生物活性 | 1.5 | 1.6 | 1.5 | 1.4 | 1.5 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.7 | 95.5 | 95.8 | 95.6 | 95.5 | |
2 | 生物活性 | 1.5 | 1.5 | 1.4 | 1.5 | 1.4 |
单聚乙二醇-干扰素α2b的纯度(%) | 96.2 | 96.0 | 95.9 | 96.1 | 95.6 | |
3 | 生物活性 | 1.5 | 1.6 | 1.5 | 1.4 | 1.5 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.2 | 95.0 | 95.2 | 95.3 | 94.9 | |
4 | 生物活性 | 1.5 | 1.5 | 1.4 | 1.5 | 1.4 |
单聚乙二醇-干扰素α2b的纯度(%) | 96.8 | 96.6 | 96.5 | 96.7 | 96.4 |
试样 | 0个月 | 6个月 | 12个月 | 18个月 | 24个月 | |
1 | 生物活性 | 1.5 | 1.5 | 1.3 | 1.2 | 0.9 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.6 | 95.5 | 94.8 | 94.5 | 94.6 | |
2 | 生物活性 | 1.5 | 1.4 | 1.1 | 0.9 | 0.7 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.9 | 95.8 | 94.8 | 95.9 | 95.6 | |
3 | 生物活性 | 1.5 | 1.5 | 1.2 | 0.9 | 0.7 |
单聚乙二醇-干扰素α2b的纯度(%) | 97.1 | 96.9 | 96.8 | 96.3 | 95.9 | |
4 | 生物活性 | 1.5 | 1.4 | 1.3 | 1.1 | 0.9 |
单聚乙二醇-干扰素α2b的纯度(%) | 96.8 | 96.5 | 96.6 | 96.3 | 95.8 |
试样 | 0个月 | 1个月 | 2个月 | 3个月 | 4个月 | 5个月 | 6个月 | |
2-1 | 生物活性 | 1.5 | 1.5 | 1.6 | 1.6 | 1.5 | 1.4 | 1.2 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.7 | 95.5 | 95.6 | 95.6 | 95.5 | 95.1 | 94.6 | |
2-2 | 生物活性 | 1.5 | 1.6 | 1.6 | 1.5 | 1.4 | 1.2 | 1.2 |
单聚乙二醇-干扰素α2b的纯度(%) | 96.2 | 96.0 | 95.9 | 96.1 | 95.6 | 95.0 | 94.9 | |
2-3 | 生物活性 | 1.5 | 1.6 | 1.5 | 1.6 | 1.4 | 1.1 | 0.8 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.2 | 95.0 | 95.2 | 95.3 | 94.8 | 94.1 | 93.6 |
试样 | 0个月 | 1个月 | 2个月 | 3个月 | 4个月 | 5个月 | 6个月 | |
3-1 | 生物活性 | 1.5 | 1.5 | 1.6 | 1.5 | 1.5 | 1.4 | 1.2 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.9 | 96.1 | 95.6 | 95.7 | 96.0 | 95.1 | 94.8 | |
3-2 | 生物活性 | 1.5 | 1.6 | 1.6 | 1.5 | 1.4 | 1.5 | 1.3 |
单聚乙二醇-干扰素α2b的纯度(%) | 96.2 | 95.8 | 95.9 | 95.0 | 95.8 | 95.6 | 95.0 |
试样 | 0个月 | 1个月 | 2个月 | 3个月 | 4个月 | 5个月 | 6个月 | |
3-1 | 生物活性 | 1.5 | 1.6 | 1.5 | 1.6 | 1.5 | 1.4 | 1.2 |
单聚乙二醇-干扰素α2b的纯度(%) | 95.8 | 96.1 | 95.6 | 95.7 | 96.0 | 95.1 | 94.8 | |
3-2 | 生物活性 | 1.6 | 1.5 | 1.6 | 1.5 | 1.4 | 1.5 | 1.2 |
单聚乙二醇-干扰素α2b的纯度(%) | 96.2 | 95.3 | 95.9 | 95.0 | 95.8 | 95.6 | 95.0 |
Claims (29)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031409555A CN1267152C (zh) | 2003-06-02 | 2003-06-02 | 聚乙二醇-干扰素α冻干制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB031409555A CN1267152C (zh) | 2003-06-02 | 2003-06-02 | 聚乙二醇-干扰素α冻干制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1513549A CN1513549A (zh) | 2004-07-21 |
CN1267152C true CN1267152C (zh) | 2006-08-02 |
Family
ID=34240326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB031409555A Expired - Fee Related CN1267152C (zh) | 2003-06-02 | 2003-06-02 | 聚乙二醇-干扰素α冻干制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1267152C (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101785856B (zh) * | 2009-01-22 | 2012-06-06 | 齐鲁制药有限公司 | 稳定等渗的去氨普酶α1或其突变体制剂 |
CN102058546B (zh) * | 2009-11-12 | 2015-07-29 | 上海市农业科学院 | 一种重组猪α-干扰素的冻干制剂及其制备方法和用途 |
CN109125713A (zh) * | 2017-06-19 | 2019-01-04 | 杭州俊丰生物工程有限公司 | 一种鸡干扰素-α药用组合物 |
CN112358541B (zh) * | 2020-11-25 | 2022-04-01 | 广州迪澳医疗科技有限公司 | 一种重组人γ-干扰素的冻干保护剂 |
-
2003
- 2003-06-02 CN CNB031409555A patent/CN1267152C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1513549A (zh) | 2004-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4971160B2 (ja) | 安定するpeg化インターフェロン処方物 | |
US7879805B2 (en) | High temperature stable peptide formulation | |
CN1117762C (zh) | 喷雾干燥的促红细胞生成素 | |
US4496537A (en) | Biologically stable alpha-interferon formulations | |
CN1130223C (zh) | 包含生长激素,氨基酸和非离子去污剂的药物配方 | |
US20060286171A1 (en) | Bone morphogenetic protein formulations | |
EP0281809B1 (en) | Sustained release compositions for parenteral administration and their use | |
CN1399560A (zh) | 新的无白蛋白的因子ⅷ制剂 | |
JP5138699B2 (ja) | Peg−インターフェロンアルファ接合体の配合物 | |
RU2010138739A (ru) | Лекарственные составы с контролируемым высвобождением, основанные на блок-сополимерах | |
JP4580744B2 (ja) | PEG−インターフェロンα結合体の保護のための処方物 | |
JP3829991B2 (ja) | Hgh含有医薬組成物 | |
CN1712067A (zh) | 冷冻干燥的不含白蛋白的重组人第ⅷ凝血因子 | |
CN1267152C (zh) | 聚乙二醇-干扰素α冻干制剂 | |
EA019345B1 (ru) | Композиции, содержащие конъюгаты пэг-интерферон-альфа и рафинозу в качестве криопротектора | |
JPH03505334A (ja) | 凍結乾燥されたペプチド製剤 | |
CN1802171A (zh) | 不包含血清白蛋白的人红细胞生成素的稳定水溶液 | |
CN1318087C (zh) | 去白蛋白神经生长因子制剂 | |
JP2013538828A (ja) | ウシ顆粒球コロニー刺激因子のための製剤およびその変異体 | |
CN1511848A (zh) | 支链聚乙二醇-集成干扰素复合物及制剂 | |
CN102327242A (zh) | 一种聚乙二醇-集成干扰素变异体冻干制剂 | |
CN102327241A (zh) | 一种聚乙二醇-集成干扰素变异体冻干制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20090116 Address after: No. 137, Xi'an Road, Changchun, Jilin Patentee after: Changchun Keygen Biological Products Co., Ltd. Address before: No. 137, Xi'an Road, Changchun, Jilin Patentee before: Changchun Research Institute of Biological Products |
|
ASS | Succession or assignment of patent right |
Owner name: CHANGCHUN QIJIAN BIOLOGY PRODUCTS CO., LTD. Free format text: FORMER OWNER: CHANGCHUN BIOLOGICAL PRODUCTS INSTITUTE Effective date: 20090116 |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060802 |